Sight Sciences Inc
sightsciences.comSight Sciences Inc (NASDAQ: SGHT) is a medical device company that develops and sells surgical and procedural devices for treating glaucoma and dry eye disease. Revenue comes entirely from product sales, split across two segments: Interventional Glaucoma and Interventional Dry Eye. Interventional Glaucoma generated $75.7M in FY2025, representing 97.9% of total revenue of $77.4M. Interventional Dry Eye, driven by the TearCare device, contributed $1.6M, or 2.1% of total revenue in FY2025, down from $4.0M in FY2024. Total gross margin was 86.2% in FY2025. TearCare is an open-eye heating and expression device designed to clear meibomian gland obstructions, the primary driver of evaporative dry eye disease. The company sells through eye care professionals, positioning its products as procedural alternatives to OTC and prescription eyedrops. Sight Sciences operates primarily in the United States, with some international activity noted in regulatory filings.
Products & Services
Interventional Glaucoma devices (unnamed in excerpts but comprising the dominant revenue segment). TearCare, an open-eye heating and expression device for meibomian gland disease treatment within the Interventional Dry Eye segment.
Revenue Model
Transactional product sales to eye care professionals. Two reported segments: Interventional Glaucoma ($75.7M, 97.9% of revenue in FY2025) and Interventional Dry Eye ($1.6M, 2.1% of revenue in FY2025). No subscription or recurring-fee structure disclosed.
Customers & Markets
Eye care professionals (ECPs) administering in-office procedures. End markets are ophthalmic surgery and dry eye disease treatment. Reimbursement from governmental and private payors is a key demand driver.
Geographic Exposure
Primary market is the United States. Some foreign jurisdictions referenced in regulatory risk disclosures, but no international revenue breakdown provided in the excerpts.
Financial Snapshot
Loading...
